1 The global prevalence of cholestasis shows an increasing trend, with estimates ranging from 19 to 402 cases per million and a notably higher incidence among females, with a female‐to‐male ratio of 9:1. 2 Cholestatic liver disease can impair the body's ability to metabolize and excrete endobiotics or xenobiotics, including drugs, potentially leading to adverse drug reactions (ADRs).
1
—
—